The rise in appendix cancer incidence: 2000-2009.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e12506-e12506
Author(s):  
Schelomo Marmor ◽  
Pamela R. Portschy ◽  
Todd M. Tuttle ◽  
Beth A. Virnig

e12506 Background: Cancer of the appendix is a rare and potentially aggressive malignancy. The objectives of this study were to characterize secular demographic patterns of disease and to determine survival by using a population-based data source. Methods: Using the Surveillance Epidemiology and End Results database we identified all appendiceal neoplasms reported to the registry between 2000 and 2009.Tumors were classified as carcinoid, adenocarcinoma, mucinous and signet ring cell carcinoma. We compared overall incidence, age distribution by tumor type and overall survival rates by extent of disease at diagnosis. To assess whether the incidence rate, tumor size, and cancer stage changed over time, the Cochrane-Armitage trend test was used. Logistic regression models were used to determine the odds of distant disease at diagnosis and Cox proportional-hazards modeling was used to identify the factors associated with overall survival rates. Results: We identified 4,765 patients with appendix cancer. The incidence of appendiceal cancer increased by 54% from 2000 (0.63 per 100,000) to 2009 (0.97 per 100,000). Incidence rates increased across all tumor types, stages, age groups and gender. The most common malignancies were mucinous (38%), followed by carcinoids (28%) adenocarcinoma (27%), and signet ring cell carcinoma (7%). Distant stage at diagnosis was most common among, signet ring cell tumors (60%). Larger tumor size and older patient age were significantly associated with higher relative odds of distant disease at diagnosis (P < .0001). Tumor type, older age, black race, males, tumor size of 2 cm and greater, cancer stage and registry were significantly associated with higher relative hazard of death (P< .0001). Mean 5-year survival was 55% for carcinoid patients, 49% for adenocarcinoma, 50% for mucinous and 38% for the signet ring cell cohort. Conclusions: Although appendiceal cancer is rare, the incidence increased significantly in the U.S. from 2000 to 2009. The cause of this trend is not obvious. We did not see increases differentially associated with stage, histology, registry or demographic characteristics. Further investigation is needed to examine factors underlying this increase. This research was generously supported by the Betti Boers Maloney Appendix Cancer Research Fund at the University of Minnesota Foundation.

2021 ◽  
Vol 10 (18) ◽  
pp. 4258
Author(s):  
Ji-Hoon Kim ◽  
Hyunil Kim ◽  
Jin Woo Kim ◽  
Hee Man Kim

Objective: Signet-ring cell carcinoma (SRCC) is a rare histopathological subtype of colorectal cancer (CRC) constituting approximately 1% of CRC cases. This study analyzed the incidence and survival rates of colorectal SRCC. Methods: We analyzed the incidence and survival rates of colorectal SRCCs based on patients’ data of the Korea Central Cancer Registry. Results: The age-standardized incidence rates of colon and rectum SRCC in 2017 were 0.17 and 0.07 individuals per 100,000, respectively. Between 1993 and 2017, the 1-, 2-, 3-, 4-, and 5-year relative survival rates of patients with colon SRCC were 65.6%, 49.0%, 38.9%, 34.9%, and 33.0%, respectively, while those of patients with rectum SRCC were 69.6%, 47.8%, 38.5%, 32.8%, and 29.4%, respectively. According to the Surveillance, Epidemiology, and End Results summary stages, the 5-year relative survival rates of colon SRCC between 1993 and 2017 were 70.4% for the localized stage, 41.0% for the regional stage, and 7.0% for the distant stage, while those for rectum SRCC were 60.7%, 34.4, and 3.3%, respectively. Conclusions: Although the incidence of colorectal SRCC is extremely low in South Korea, it has been increasing in recent decades. As the prognosis of colorectal SRCC is extremely poor; clinicians should be aware of the differential diagnosis of SRCC in colorectal cancer cases.


2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 488-488 ◽  
Author(s):  
John Khoury ◽  
Rebecca Chacko ◽  
David Macari ◽  
Bolanle Gbadamosi ◽  
Daniel Ezekwudo ◽  
...  

488 Background: Signet ring cell carcinoma of the colon (SRCC) represents less than 1% of all colon carcinomas. We retrospectively examined the metastatic patterns and prognosis of SRCC in comparison to adenocarcinoma (AC) of the colon. Methods: A total of 763 patients diagnosed with SRCC and 42,875 patients with AC of the colon from 2010 to 2012 were identified from the Surveillance, Epidemiology and End Results (SEER) database. Age, race, gender, primary site, grade, stage, metastatic site and survival data were collected. Results: Out of 43,638 patients, 78.7% were white, 12.5% black and 8.8% other races. Median age of diagnosis was 67.5 years for SRCC as compared to 69.1 years for AC . SRCC was more likely to be grade III or IV (92% vs 21.6%; p < 0.001), to be found in the right colon (63.7% vs 49.4%; p < 0.001) and to present as advanced stage (40.2% vs 29.4% for stage III and 37.1% vs 22.3% for stage IV; p < 0.001). SRCC was more likely to present with metastases to the brain (11.0% vs 1.3%; p < 0.001) and bone (6.4% vs 4.1%; p < 0.001), while AC subjects were more likely to present with metastases to the liver (77.0% vs 22.1%; p < 0.001) and lung (21.2% vs 5.8%; p < 0.001). The 5 year overall survival rate (5-YSR) was 28.2% (CI, 24.5% to 32.4%) for SRCC compared to 50.8% (CI, 50.1% to 51.6%) for AC (Hazard ratio for death, 1.38; CI, 1.26 to 1.52; P < 0.001). The differences in stage specific 5-year survival rates for SRCC and AC were not statistically significant for stage I and stage II. However, SRCC had a lower 5-YSR for stage III (34.5% vs 55.4%) and stage IV (3.3% vs 10.8%). Conclusions: SRCC of the colon has worse survival rates for advanced stages when compared to AC. SRCC presents at earlier age, with advanced tumor grade and stage at diagnosis. The metastatic behavior of SRCC is different than AC with a higher incidence of brain and bone metastases at diagnosis.


Author(s):  
Wang C ◽  
◽  
Li H ◽  
Luo J ◽  
Liu R ◽  
...  

Objective: To investigate the effect of radiotherapy on prognosis in gastric signet ring cell carcinoma (SRCC) and gastric non-signet ring cell adenocarcinoma (NSRCC) patients. Methods: A total of 23,971 patients diagnosed with gastric cancer were collected from 2004 to 2013 by SEER database, including 17,679 NSRCC patients and 6,292 SRCC patients. Patients were divided to two groups and compared according to whether radical gastrectomy was performed on them. After clinic pathological characteristics of the two groups were balanced by the propensity score matching (PSM) method, survival rates of the two groups were then compared. Results: The Over Survival (OS) and Cancer-Specific Survival (CSS) time of SRCC and NSRCC patients in the radiotherapy groupwere significantly better than those in the non-radiotherapy group. But the clinical and pathological characteristics (gender, age, pathological differentiation degree, T stage, N stage, and metastasis) of the two groups were significantly unbalanced (p<0.001). After 1:1 PSM matching, it was found that radiotherapy had no significant effect on OS and CSS time of NSRCC patients, but radiotherapy could significantly improve OS and CSS time of SRCC patients. Conclusion: SRCC patients are more sensitive to radiotherapy than NSRCC patients. Although the prognosis of SRCC is far less than that of NSRCC patients, the treatment strategy of surgical resection of primary lesions combined with radiotherapy should be recommend for SRCC patients, and whether radiotherapy benefits NSRCC patients still needs to be further studied.


2020 ◽  
Vol 2 (3) ◽  
Author(s):  
Ines Zemni ◽  
Houyem Mansouri ◽  
Ines Ben Safta ◽  
Mohamed Ali Ayadi ◽  
Tarek Ben Dhiab ◽  
...  

Background: Gastric signet ring cell carcinoma (SRCC) appears to have clinical features and survival rates particularly different from other histological types. The aim of this study was to investigate clinicopathological features and survival outcomes of SRCC and to compare them with non-signet ring cell carcinoma (NSRCC). Methods: We retrospectively studied 145 patients with non-metastatic gastric carcinoma who underwent gastrectomy in our institute from 2005 to 2015. Among them, 36 patients (9.4%) with SRCC were compared to 109 patients (90.6%) with NSRCC. Results: Patients with SRCC presented at a younger age (p=0.001) with more advanced stage III-IV disease (p=0.005) and advanced N stages with a higher rate of pN3 (p=0.0001), a higher number of invaded lymph nodes (p=0.002) and a higher rate of patients with a lymph node ratio exceeding 25% (63.9% vs 36.7, p=0.004). After a median follow up of 35.30 months, there was no significant difference in the 5 years overall (OS) survival between SRCC and NSRCC ((36.7% vs 45.7%, p=0.206).However, the 5 years progressive free survival (PFS) was significantly decreased in case of SRCC (38.7% vs 50.9%, p=0.038) with a higher rate of metastasis in (52.9% vs 29.5%, p=0.013) and peritoneal recurrence (35.3% vs 9.5%, p<0.0001). The main prognostic factors of PFS and OS in SRCC were tumoral stenosis, hypoprotidemia, tumor size, depth of invasion (p=0.001), perineural and lymphovascular invasion, the UICC stage and complete surgical resection. Conclusion: Gastric SRCC have a particular clinicopathological behavior compared to NSRCC suggesting its more aggressive character.


2021 ◽  
Author(s):  
Di Zhou ◽  
Yong-jing Yang ◽  
Chun-cao Niu ◽  
Yong-jiang Yu ◽  
Jian-dong Diao

Abstract Objective: To evaluate the prognostic value of age on colorectal signet ring cell carcinoma (SRCC) and identify the prognosis factors of patients aged ≥ 65 years.Methods: Patients were recruited from the Surveillance, Epidemiology, and End Results (SEER) database. We ensured that all characteristics were well balanced through adopting the propensity score matching (PSM) method. In addition, the prognostic factors were evaluated by the Cox proportional hazardous model.Results: Altogether 3305 cases were enrolled, including 1564 in elderly group (aged ³65 years). As a result, more patients were female, unmarried, white, earlier AJCC stage, tumor size ≤5cm, grade III/IV and located in cecum–transverse colon in the elderly group; whereas significant fewer patients received chemotherapy and radiotherapy. After 1:1 PSM analysis, each group contained 1032 cases. As discovered by Kaplan-Meier analysis, the elderly group was associated with remarkably dismal survival compared with the younger group after PSM analysis (P=0.0091).Moreover, grade, primary site, AJCC stage, tumor size, surgery and chemotherapy were identified as the independent prognostic factors for the elderly patients.Conclusion: The prognosis of colorectal SRCC aged ≥ 65 years was worse than the younger patients. We may need strengthen the chemotherapy of the eldly colorectal SRCC.


2021 ◽  
Vol 12 (7) ◽  
pp. 1122-1125
Author(s):  
Alberto Testori ◽  
Gianluca Perroni ◽  
Camilla De Carlo ◽  
Alessandro Crepaldi ◽  
Marco Alloisio ◽  
...  

2021 ◽  
Vol 28 (1) ◽  
pp. 918-927
Author(s):  
Lei-Chi Wang ◽  
Tai-Chi Lin ◽  
Yi-Chen Yeh ◽  
Hsiang-Ling Ho ◽  
Chieh-Chih Tsai ◽  
...  

Primary signet ring cell/histiocytoid carcinoma of the eyelid is a rare ocular malignancy and its diagnosis is often delayed. This neoplasm presents as an insidious, diffusely infiltrative mass in the periocular area that later infiltrates the orbit. An exenteration is usually indicated; however, nearly one-third of patients develop local recurrence or metastasis. Morphologically, it resembles signet ring cell carcinoma of the stomach and breast, raising the possibility of mutations in CDH1, the gene encoding E-cadherin. To determine whether primary signet ring cell/histiocytoid carcinoma harbors the CDH1 mutation or other actionable mutations, we analyzed the tumor tissue via next-generation sequencing. We identified only one case of primary signet ring cell carcinoma of the eyelid with adequate DNA quality for sequencing from the pathological archive during the period 2000 to 2020. A comprehensive evaluation including histopathology, immunohistochemistry, and next-generation sequencing assay was performed on tumor tissue. Immunohistochemically, the tumor exhibited E-cadherin membranous staining with the aberrant cytoplasmic staining of β-catenin. Using next-generation sequencing, we demonstrated the mutation in the CDH1 gene. In addition, other clinically actionable mutations including ERBB2 and PIK3CA were also detected. The alterations in other actionable genes indicate a need for larger studies to evaluate the pathogenesis and potential therapies for primary signet ring cell/histiocytoid carcinoma of the eyelid.


2021 ◽  
pp. 106689692199418
Author(s):  
John D. Coyne ◽  
S. Thampy

Pseudo-signet ring parietal cell vacuolation has been described as a mimic of invasive signet ring cell carcinoma. Moreover, signet ring cell carcinoma has been described in a fundic gland polyp. This case demonstrates parietal cell vacuolation in a fundic gland polyp in a patient on a long-term proton pump inhibitor.


Sign in / Sign up

Export Citation Format

Share Document